# Boundless Bio, Inc.: financial statements, quarterly

BOLD · Nasdaq · CIK 1782303 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bold.md) · [Financials](/companies/bold/financials.md) · [Filings](/companies/bold/filings.md) · [Insiders](/companies/bold/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bold/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [11.6](/filings/0000950170-24-123291.md) | [10.4 d](/filings/0000950170-25-045725.md) | [13.1](/filings/0000950170-25-067496.md) | [14.7](/filings/0000950170-25-102391.md) | [14.1](/filings/0001193125-25-265714.md) | [13.3 d](/filings/0001193125-26-097543.md) | [12.1](/filings/0001193125-26-213321.md) | [12.2](/filings/0001193125-26-339093.md) | [10.7](/filings/0001193125-25-265714.md) | [9.8 d](/filings/0001193125-26-097543.md) | [9.7](/filings/0001193125-26-213321.md) | [14.0](/filings/0001193125-26-339093.md) |
| Operating income | $m | [(15.0)](/filings/0000950170-24-123291.md) | [(13.8) d](/filings/0000950170-25-045725.md) | [(16.9)](/filings/0000950170-25-067496.md) | [(19.4)](/filings/0000950170-25-102391.md) | [(18.7)](/filings/0001193125-25-265714.md) | [(18.3) d](/filings/0001193125-26-097543.md) | [(17.3)](/filings/0001193125-26-213321.md) | [(17.1)](/filings/0001193125-26-339093.md) | [(15.1)](/filings/0001193125-25-265714.md) | [(14.0) d](/filings/0001193125-26-097543.md) | [(14.5)](/filings/0001193125-26-213321.md) | [(24.4)](/filings/0001193125-26-339093.md) |
| Net income | $m | [(13.2)](/filings/0000950170-24-123291.md) | [(12.1) d](/filings/0000950170-25-045725.md) | [(15.4)](/filings/0000950170-25-067496.md) | [(17.0)](/filings/0000950170-25-102391.md) | [(16.5)](/filings/0001193125-25-265714.md) | [(16.4) d](/filings/0001193125-26-097543.md) | [(15.8)](/filings/0001193125-26-213321.md) | [(15.7)](/filings/0001193125-26-339093.md) | [(13.9)](/filings/0001193125-25-265714.md) | [(12.9) d](/filings/0001193125-26-097543.md) | [(13.6)](/filings/0001193125-26-213321.md) | [(23.7)](/filings/0001193125-26-339093.md) |
| Diluted EPS | $ per share | [(10.71)](/filings/0000950170-24-123291.md) | not reported | [(12.27)](/filings/0000950170-25-067496.md) | [(0.77)](/filings/0000950170-25-102391.md) | [(0.74)](/filings/0001193125-25-265714.md) | not reported | [(0.71)](/filings/0001193125-26-213321.md) | [(0.70)](/filings/0001193125-26-339093.md) | [(0.62)](/filings/0001193125-25-265714.md) | not reported | [(0.60)](/filings/0001193125-26-213321.md) | [(1.06)](/filings/0001193125-26-339093.md) |
| Basic EPS | $ per share | [(10.71)](/filings/0000950170-24-123291.md) | not reported | [(12.27)](/filings/0000950170-25-067496.md) | [(0.77)](/filings/0000950170-25-102391.md) | [(0.74)](/filings/0001193125-25-265714.md) | not reported | [(0.71)](/filings/0001193125-26-213321.md) | [(0.70)](/filings/0001193125-26-339093.md) | [(0.62)](/filings/0001193125-25-265714.md) | not reported | [(0.60)](/filings/0001193125-26-213321.md) | [(1.06)](/filings/0001193125-26-339093.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [21.0](/filings/0000950170-24-123291.md) | [23.7](/filings/0000950170-25-045725.md) | [25.1](/filings/0000950170-25-067496.md) | [31.4](/filings/0000950170-25-102391.md) | [40.2](/filings/0001193125-25-265714.md) | [26.6](/filings/0001193125-26-097543.md) | [15.1](/filings/0001193125-26-213321.md) | [14.7](/filings/0001193125-26-339093.md) | [15.0](/filings/0001193125-25-265714.md) | [17.9](/filings/0001193125-26-339093.md) | [17.5](/filings/0001193125-26-213321.md) | [20.2](/filings/0001193125-26-339093.md) |
| Current assets | $m | not reported | [124](/filings/0000950170-25-045725.md) | [112](/filings/0000950170-24-058188.md) | [183](/filings/0000950170-24-095421.md) | [170](/filings/0000950170-24-123291.md) | [154](/filings/0001193125-26-097543.md) | [140](/filings/0000950170-25-067496.md) | [130](/filings/0000950170-25-102391.md) | [120](/filings/0001193125-25-265714.md) | [110](/filings/0001193125-26-339093.md) | [94.6](/filings/0001193125-26-213321.md) | [73.6](/filings/0001193125-26-339093.md) |
| Total assets | $m | not reported | [130](/filings/0000950170-25-045725.md) | [117](/filings/0000950170-24-058188.md) | [188](/filings/0000950170-24-095421.md) | [175](/filings/0000950170-24-123291.md) | [206](/filings/0001193125-26-097543.md) | [191](/filings/0000950170-25-067496.md) | [179](/filings/0000950170-25-102391.md) | [169](/filings/0001193125-25-265714.md) | [157](/filings/0001193125-26-339093.md) | [141](/filings/0001193125-26-213321.md) | [73.7](/filings/0001193125-26-339093.md) |
| Current liabilities | $m | not reported | [9.4](/filings/0000950170-25-045725.md) | [10.6](/filings/0000950170-24-058188.md) | [9.0](/filings/0000950170-24-095421.md) | [10.0](/filings/0000950170-24-123291.md) | [8.1](/filings/0001193125-26-097543.md) | [6.3](/filings/0000950170-25-067496.md) | [9.2](/filings/0000950170-25-102391.md) | [11.8](/filings/0001193125-25-265714.md) | [12.5](/filings/0001193125-26-339093.md) | [9.6](/filings/0001193125-26-213321.md) | [7.8](/filings/0001193125-26-339093.md) |
| Total liabilities | $m | not reported | [9.4](/filings/0000950170-25-045725.md) | not reported | not reported | not reported | [55.8](/filings/0001193125-26-097543.md) | [54.7](/filings/0000950170-25-067496.md) | [56.8](/filings/0000950170-25-102391.md) | [58.6](/filings/0001193125-25-265714.md) | [58.4](/filings/0001193125-26-339093.md) | [54.6](/filings/0001193125-26-213321.md) | [7.8](/filings/0001193125-26-339093.md) |
| Shareholders' equity | $m | [(116)](/filings/0000950170-24-123291.md) | [(127)](/filings/0000950170-25-045725.md) | [(141)](/filings/0000950170-24-058188.md) | [179](/filings/0000950170-24-095421.md) | [165](/filings/0000950170-24-123291.md) | [151](/filings/0001193125-26-097543.md) | [137](/filings/0000950170-25-067496.md) | [123](/filings/0000950170-25-102391.md) | [110](/filings/0001193125-25-265714.md) | [98.7](/filings/0001193125-26-339093.md) | [86.4](/filings/0001193125-26-213321.md) | [66.0](/filings/0001193125-26-339093.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(12.2) d](/filings/0000950170-24-123291.md) | [(11.7) d](/filings/0000950170-25-045725.md) | [(15.8)](/filings/0000950170-25-067496.md) | [(16.2) d](/filings/0000950170-25-102391.md) | [(13.3) d](/filings/0001193125-25-265714.md) | [(15.6) d](/filings/0001193125-26-097543.md) | [(14.5)](/filings/0001193125-26-213321.md) | [(11.8) d](/filings/0001193125-26-339093.md) | [(10.2) d](/filings/0001193125-25-265714.md) | [(10.1) d](/filings/0001193125-26-097543.md) | [(15.0)](/filings/0001193125-26-213321.md) | [(21.0) d](/filings/0001193125-26-339093.md) |
| Capital expenditure | $m | [0.2 d](/filings/0000950170-24-123291.md) | [0.3 d](/filings/0000950170-25-045725.md) | [0.1](/filings/0000950170-25-067496.md) | [1.5 d](/filings/0000950170-25-102391.md) | [0.5 d](/filings/0001193125-25-265714.md) | [0.5 d](/filings/0001193125-26-097543.md) | [0.1](/filings/0001193125-26-213321.md) | [0.0 d](/filings/0001193125-26-339093.md) | [0.0 d](/filings/0001193125-25-265714.md) | [0.4 d](/filings/0001193125-26-097543.md) | [0.0](/filings/0001193125-26-213321.md) | [0.0 d](/filings/0001193125-26-339093.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.2](/filings/0000950170-24-058188.md) | [1.2](/filings/0000950170-24-095421.md) | [1.2](/filings/0000950170-24-123291.md) | [1.3](/filings/0000950170-25-067496.md) | [22.0](/filings/0000950170-25-102391.md) | [22.3](/filings/0001193125-25-265714.md) | [22.3](/filings/0001193125-26-213321.md) | [22.4](/filings/0001193125-26-339093.md) | [22.4](/filings/0001193125-25-265714.md) | [22.4](/filings/0001193125-26-213321.md) | [22.5](/filings/0001193125-26-339093.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 22,747,985 at 2026-08-05, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-339093.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.